Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01581970 · ClinicalTrials.gov registry record · Phase 2
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01581970 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 7 participants.
The verdict
NCT01581970, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a feasibility study to assess the effectiveness of cetuximab when administered with low dose oral cyclophosphamide. Patients with metastatic squamous cell cancer of head and neck who have progressed on first line chemotherapy other than a cetuximab containing regimen will be treated with standard of care weekly cetuximab and twice daily low dose oral cyclophosphamide for 12 weeks.
Interventions
- DRUG Cyclophosphamide
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01581970
The ClinicalTrials.gov registry entry for NCT01581970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT01581970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01581970 about?
NCT01581970 is a clinical study titled "Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer". This is a feasibility study to assess the effectiveness of cetuximab when administered with low dose oral cyclophosphamide. Patients with metastatic squamous cell cancer of head and neck who have progressed on first line chemotherapy other than a cetuximab containing regimen will be treated with sta...
What is the current status of trial NCT01581970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2012-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01581970?
The interventions under investigation include: Cyclophosphamide (DRUG), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT01581970?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.